department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Mavyret · pharmadog

pharmadog
drugs
Mavyret

drug

patient view →

(glecaprevir + pibrentasvir)

Marketedupdated 2mo ago

by $ABBV AbbVie Inc.

Approved

annual revenue · 2024–2024peak $1.4B

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Mavyret

generic

(glecaprevir + pibrentasvir)

indication

Hepatitis C

phase

marketed

approved

2017-08-03

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 30, 2026

115 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (36)

Dec 24, 2036patentUS 11246866*PED
Jun 24, 2036formulationUS 11246866
Dec 5, 2035patentUS 9321807*PED
Dec 5, 2035patentUS 9321807*PED
Nov 8, 2035patentUS RE48923*PED
Nov 8, 2035patentUS RE48923*PED
Jun 5, 2035compositionUS 9321807
Jun 5, 2035compositionUS 9321807
May 8, 2035compositionUS RE48923
May 8, 2035compositionUS RE48923
Sep 14, 2034patentUS 10286029*PED
Sep 14, 2034patentUS 10286029*PED
Sep 14, 2034patentUS 11484534*PED
Mar 14, 2034method-of-use (U-3238)US 10286029
Mar 14, 2034method-of-use (U-3237)US 10286029
Mar 14, 2034method-of-use (U-3237)US 11484534
Nov 18, 2032patentUS 8937150*PED
Nov 18, 2032patentUS 8937150*PED
Jul 19, 2032patentUS 8648037*PED
Jul 19, 2032patentUS 8648037*PED
May 18, 2032compositionUS 8937150
May 18, 2032compositionUS 8937150
Jan 19, 2032compositionUS 8648037
Jan 19, 2032compositionUS 8648037
May 6, 2031patentUS 9586978*PED4.8y
May 6, 2031patentUS 9586978*PED4.8y
Dec 10, 2030patentUS 10028937*PED4.4y
Dec 10, 2030patentUS 10028937*PED4.4y
Dec 10, 2030patentUS 10039754*PED4.4y
Dec 10, 2030patentUS 10039754*PED4.4y
Nov 6, 2030method-of-use (U-3238)US 95869784.3y
Nov 6, 2030method-of-use (U-2141)US 95869784.3y
Jun 10, 2030method-of-use (U-3237)US 100289373.9y
Jun 10, 2030method-of-use (U-3238)US 100289373.9y
Jun 10, 2030method-of-use (U-3238)US 100397543.9y
Jun 10, 2030method-of-use (U-3237)US 100397543.9y

FDA exclusivities (9)

Dec 10, 2028PEDPediatric (6mo bonus)2.4y
Dec 10, 2028PEDPediatric (6mo bonus)2.4y
Jun 10, 2028I-967Indication (3y)1.9y
Jun 10, 2028ODE-372Orphan Drug (7y)1.9y
Jun 10, 2028I-967Indication (3y)1.9y
Jun 10, 2028ODE-372Orphan Drug (7y)1.9y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Oct 30, 2026PEDPediatric (6mo bonus)115d

Apr 30, 2026ODE-233Orphan Drug (7y)

Apr 30, 2026ODE-232Orphan Drug (7y)

Trials studying (glecaprevir + pibrentasvir)

phase2Transplanting Hepatitis C Kidneys Into Negative Kidney Recipientscompletedn=62